SG11202000124PA - Promoting hair growth and treatment of hair loss or excessive hair shedding - Google Patents
Promoting hair growth and treatment of hair loss or excessive hair sheddingInfo
- Publication number
- SG11202000124PA SG11202000124PA SG11202000124PA SG11202000124PA SG11202000124PA SG 11202000124P A SG11202000124P A SG 11202000124PA SG 11202000124P A SG11202000124P A SG 11202000124PA SG 11202000124P A SG11202000124P A SG 11202000124PA SG 11202000124P A SG11202000124P A SG 11202000124PA
- Authority
- SG
- Singapore
- Prior art keywords
- hair
- international
- subject
- shedding
- excessive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017902722A AU2017902722A0 (en) | 2017-07-12 | Promoting hair growth and treatment of hair loss or excessive hair shedding | |
| PCT/AU2018/050719 WO2019010535A1 (en) | 2017-07-12 | 2018-07-12 | STIMULATION OF HAIR GROWTH AND TREATMENT OF HAIR FALL OR EXCESSIVE ALOPECIA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000124PA true SG11202000124PA (en) | 2020-02-27 |
Family
ID=65001077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000124PA SG11202000124PA (en) | 2017-07-12 | 2018-07-12 | Promoting hair growth and treatment of hair loss or excessive hair shedding |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190269684A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3651769B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7191927B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240064747A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111065396A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018250398B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3069336A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2909395T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202000124PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019010535A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ732075A (en) | 2014-10-29 | 2022-09-30 | Samson Clinical Pty Ltd | Detection and treatment of excessive hair shedding |
| GB2596942B (en) | 2019-02-27 | 2023-05-10 | Samson Clinical Pty Ltd | Tofacitinib via oral mucosa for use in treatment of autoimmune hair loss or excessing hair shedding |
| WO2021178871A1 (en) | 2020-03-05 | 2021-09-10 | University Of Miami | Cannabidiol nanodrug formulations and methods for use the same |
| CN112691187B (zh) * | 2020-12-30 | 2021-12-21 | 深圳新发源植物科技发展有限公司 | 一种用于防止额前脱发的缓释膜及其制备方法 |
| CN113248501B (zh) * | 2021-06-17 | 2021-10-08 | 南京韦尔优众医药有限公司 | Cly系列化合物及其制备方法和制备药物的用途 |
| KR20250100660A (ko) | 2022-10-25 | 2025-07-03 | 베라더믹스 인코포레이티드 | 변형 방출 미녹시딜의 조성물 및 사용 방법 |
| EP4539816A4 (en) * | 2023-09-01 | 2025-07-23 | Follea Int | COMPOSITIONS AND METHODS FOR AN ORALLY ADMINISTERED MINOXIDIL SUPPLEMENT FOR THE TREATMENT OF ALOPECIA |
| KR20260065905A (ko) * | 2023-09-08 | 2026-05-11 | 수조우 킨터 제약회사(주) | 안드로겐 수용체 억제제/길항제를 함유하는 약학 조성물, 방법 및 용도 |
| GB2638418A (en) * | 2024-02-21 | 2025-08-27 | Novumgen Ltd | An orodispersible tablet of spironolactone and its process of preparation |
| WO2026062695A1 (en) * | 2024-09-17 | 2026-03-26 | Shah Atul K | Toothpaste for body disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997643A (en) * | 1989-07-12 | 1991-03-05 | Union Carbide Chemicals And Plastics Company Inc. | Polymeric salt delivery systems |
| GB2314019B (en) * | 1996-06-10 | 2000-03-15 | Bio Scient Ltd | The use of L-Lysine in the treatment of hair loss |
| WO1999040898A2 (en) * | 1998-02-12 | 1999-08-19 | Centrapharm Inc. | Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect |
| US20050271596A1 (en) * | 2002-10-25 | 2005-12-08 | Foamix Ltd. | Vasoactive kit and composition and uses thereof |
| CN1838969A (zh) * | 2004-10-07 | 2006-09-27 | 三仪股份有限公司 | 经皮和经粘膜制剂 |
| JP2009091325A (ja) * | 2007-10-11 | 2009-04-30 | Rohto Pharmaceut Co Ltd | 育毛剤 |
| EP2344198B1 (en) * | 2008-09-27 | 2020-11-04 | Jina Pharmaceuticals Inc. | Lipid based pharmaceutical preparations for topical application |
| EP2510930A1 (en) * | 2011-04-15 | 2012-10-17 | Bionanoplus, S.L. | Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof |
| AU2011100917B4 (en) * | 2011-07-26 | 2013-05-02 | Sinclair, Rodney Daniel Professor | Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens |
| WO2013181487A2 (en) * | 2012-05-31 | 2013-12-05 | Stiefel Laboratories, Inc. | Method of treating |
| NZ732075A (en) * | 2014-10-29 | 2022-09-30 | Samson Clinical Pty Ltd | Detection and treatment of excessive hair shedding |
| US9561224B1 (en) * | 2015-05-27 | 2017-02-07 | Moshe Rogosnitzky | Methods and compositions for treating androgenetic alopecia |
-
2018
- 2018-07-12 KR KR1020247014382A patent/KR20240064747A/ko not_active Ceased
- 2018-07-12 CN CN201880057079.8A patent/CN111065396A/zh active Pending
- 2018-07-12 AU AU2018250398A patent/AU2018250398B2/en active Active
- 2018-07-12 SG SG11202000124PA patent/SG11202000124PA/en unknown
- 2018-07-12 US US16/344,288 patent/US20190269684A1/en not_active Abandoned
- 2018-07-12 EP EP18832869.4A patent/EP3651769B1/en active Active
- 2018-07-12 KR KR1020207002802A patent/KR102663164B1/ko active Active
- 2018-07-12 ES ES18832869T patent/ES2909395T3/es active Active
- 2018-07-12 JP JP2020501509A patent/JP7191927B2/ja active Active
- 2018-07-12 CA CA3069336A patent/CA3069336A1/en active Pending
- 2018-07-12 WO PCT/AU2018/050719 patent/WO2019010535A1/en not_active Ceased
-
2019
- 2019-05-16 AU AU2019203438A patent/AU2019203438A1/en not_active Abandoned
-
2022
- 2022-12-07 JP JP2022195386A patent/JP2023016964A/ja not_active Withdrawn
-
2024
- 2024-11-08 US US18/942,149 patent/US20250064807A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018250398B2 (en) | 2019-02-28 |
| WO2019010535A1 (en) | 2019-01-17 |
| AU2019203438A1 (en) | 2019-06-06 |
| AU2018250398A1 (en) | 2019-01-31 |
| CN111065396A (zh) | 2020-04-24 |
| ES2909395T3 (es) | 2022-05-06 |
| KR20240064747A (ko) | 2024-05-13 |
| JP2023016964A (ja) | 2023-02-02 |
| CA3069336A1 (en) | 2019-01-17 |
| US20190269684A1 (en) | 2019-09-05 |
| EP3651769A1 (en) | 2020-05-20 |
| JP7191927B2 (ja) | 2022-12-19 |
| EP3651769B1 (en) | 2022-01-05 |
| US20250064807A1 (en) | 2025-02-27 |
| KR102663164B1 (ko) | 2024-05-07 |
| NZ760579A (en) | 2024-09-27 |
| EP3651769A4 (en) | 2021-04-21 |
| JP2020527146A (ja) | 2020-09-03 |
| BR112020000508A2 (pt) | 2020-07-14 |
| KR20200028403A (ko) | 2020-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
| SG11201810872UA (en) | Composition and method for reducing neutropenia | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
| SG11201909882SA (en) | Targeted neoepitope vectors and methods therefor | |
| SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201909107YA (en) | Stenosis treatment | |
| SG11201811763SA (en) | B-cell-mimetic cells | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201907950VA (en) | Complexes for treating sensitivity |